Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cho-Chin Cheng

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Computational and Structural Biotechnology Journal|February 7, 2022
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposingMax Luedemann, Daniela Stadler, Cho-Chin Cheng, et al.
Antiviral Research|November 14, 2021
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion proteinHristo L Svilenov, Julia Sacherl, Alwin Reiter, et al.
Nucleic Acids Research|December 20, 2021
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spreadShubhankar Ambike, Cho-Chin Cheng, Martin Feuerherd, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 1, 2022
Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexesDomizia Baldassi, Shubhankar Ambike, Martin Feuerherd, et al.
Nature Communications|July 28, 2023
Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damageChristina Beck, Deepak Ramanujam, Paula Vaccarello, et al.
Vaccines|August 26, 2022
Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis PatientsCho-Chin Cheng, Louise Platen, Catharina Christa, et al.
Vaccines|March 28, 2024
SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 VaccineBo-Hung Liao, Louise Platen, Myriam Grommes, et al.
Frontiers in Immunology|April 17, 2023
Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipientsNina Körber, Christopher Holzmann-Littig, Gesa Wilkens, et al.
Clinical Kidney Journal|December 4, 2023
Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patientsLouise Platen, Bo-Hung Liao, Myriam Tellenbach, et al.
Nature Communications|January 11, 2022
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescentsNina Koerber, Alina Priller, Sarah Yazici, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Computational and Structural Biotechnology Journal|February 7, 2022
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposingMax Luedemann, Daniela Stadler, Cho-Chin Cheng, et al.
Antiviral Research|November 14, 2021
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion proteinHristo L Svilenov, Julia Sacherl, Alwin Reiter, et al.
Nucleic Acids Research|December 20, 2021
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spreadShubhankar Ambike, Cho-Chin Cheng, Martin Feuerherd, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 1, 2022
Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexesDomizia Baldassi, Shubhankar Ambike, Martin Feuerherd, et al.
Nature Communications|July 28, 2023
Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damageChristina Beck, Deepak Ramanujam, Paula Vaccarello, et al.
Vaccines|August 26, 2022
Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis PatientsCho-Chin Cheng, Louise Platen, Catharina Christa, et al.
Vaccines|March 28, 2024
SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 VaccineBo-Hung Liao, Louise Platen, Myriam Grommes, et al.
Frontiers in Immunology|April 17, 2023
Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipientsNina Körber, Christopher Holzmann-Littig, Gesa Wilkens, et al.
Clinical Kidney Journal|December 4, 2023
Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patientsLouise Platen, Bo-Hung Liao, Myriam Tellenbach, et al.
Nature Communications|January 11, 2022
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescentsNina Koerber, Alina Priller, Sarah Yazici, et al.
Pageof 2